Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Here's What You Missed in Cannabis This Week » 12:54
08/18/22
08/18
12:54
08/18/22
12:54
CANN

General Cannabis

/

+

, GTBIF

Green Thumb Industries

$10.47 /

-0.6 (-5.42%)

, CCHWF

Columbia Care

$1.82 /

-0.06 (-3.19%)

, FLGC

Flora Growth

/

+

, CVSI

CV Sciences

/

+

, DLTNF

Delta 9 Cannabis

/

+

, IMCC

IM Cannabis

/

+

, MEDIF

Medipharm Labs

/

+

, FFNTF

4Front Ventures

/

+

, INCR

InterCure

$5.78 /

-0.04 (-0.69%)

, NEPT

Neptune Wellness

$3.07 /

+1.71 (+125.74%)

, PLNHF

Planet 13 Holdings

$1.69 /

-0.1 (-5.59%)

, GNLN

Greenlane

$3.45 /

-0.13 (-3.63%)

, NDVAF

INDIVA

/

+

, VRNOF

Verano Holdings

$5.61 /

-0.09 (-1.58%)

, CRLBF

Cresco Labs

$3.63 /

-0.12 (-3.20%)

, AYRWF

Ayr Wellness

$4.54 /

-0.09325 (-2.01%)

, ATAI

Atai Life Sciences

$4.61 /

+0.09 (+1.99%)

, RVLWF

Revitalist Lifestyle and Wellness

/

+

, AWKNF

Awakn Life Sciences

/

+

, TLRY

Tilray

$3.95 /

-0.105 (-2.59%)

, ACB

Aurora Cannabis

$1.66 /

-0.08 (-4.60%)

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$3.80 /

-0.27 (-6.64%)

, CRON

Cronos Group

$3.10 /

-0.105 (-3.28%)

, IGC

India Globalization Capital

/

+

, TCNNF

Trulieve Cannabis

$12.81 /

-0.38 (-2.88%)

, ZYNE

Zynerba

$1.24 /

-0.075 (-5.70%)

, CMPS

Compass Pathways

$16.95 /

-0.02 (-0.12%)

, RLMD

Relmada Therapeutics

$27.56 /

-0.52 (-1.85%)

, GDNSF

Goodness Growth

$1.11 /

-0.033 (-2.89%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
$1.24 /

-0.075 (-5.70%)

VRNOF Verano Holdings
$5.61 /

-0.09 (-1.58%)

TLRY Tilray
$3.95 /

-0.105 (-2.59%)

TCNNF Trulieve Cannabis
$12.81 /

-0.38 (-2.88%)

RVLWF Revitalist Lifestyle and Wellness
/

+

RLMD Relmada Therapeutics
$27.56 /

-0.52 (-1.85%)

PLNHF Planet 13 Holdings
$1.69 /

-0.1 (-5.59%)

NEPT Neptune Wellness
$3.07 /

+1.71 (+125.74%)

MEDIF Medipharm Labs
/

+

INCR InterCure
$5.78 /

-0.04 (-0.69%)

IMCC IM Cannabis
/

+

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$10.47 /

-0.6 (-5.42%)

GNLN Greenlane
$3.45 /

-0.13 (-3.63%)

GDNSF Goodness Growth
$1.11 /

-0.033 (-2.89%)

FLGC Flora Growth
/

+

DLTNF Delta 9 Cannabis
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$3.10 /

-0.105 (-3.28%)

CMPS Compass Pathways
$16.95 /

-0.02 (-0.12%)

CGC Canopy Growth
$3.80 /

-0.27 (-6.64%)

CCHWF Columbia Care
$1.82 /

-0.06 (-3.19%)

AYRWF Ayr Wellness
$4.54 /

-0.09325 (-2.01%)

ATAI Atai Life Sciences
$4.61 /

+0.09 (+1.99%)

ACB Aurora Cannabis
$1.66 /

-0.08 (-4.60%)

CANN General Cannabis
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
GTBIF Green Thumb Industries
$10.47 /

-0.6 (-5.42%)

08/04/22 Canaccord
Green Thumb Industries price target lowered to C$35 from C$40 at Canaccord
08/04/22 Stifel
Green Thumb Industries price target raised to C$30.50 from C$30 at Stifel
08/04/22 Alliance Global Partners
Green Thumb Industries price target lowered to C$25 at Alliance Global Partners
08/04/22 Cantor Fitzgerald
Green Thumb Industries price target lowered to $31 from $39 at Cantor Fitzgerald
CCHWF Columbia Care
$1.82 /

-0.06 (-3.19%)

08/15/22 Alliance Global Partners
Columbia Care price target lowered to C$5 from C$8 at Alliance Global Partners
05/18/22 Canaccord
Columbia Care price target lowered to C$4.50 from C$6 at Canaccord
05/16/22 Alliance Global Partners
Columbia Care price target lowered to C$8 from C$9 at Alliance Global Partners
03/24/22 Stifel
Cresco Labs downgraded to Hold from Buy at Stifel
FLGC Flora Growth
/

+

08/01/22 Cantor Fitzgerald
Cantor starts Flora Growth with Neutral amid diversification process
08/01/22 Cantor Fitzgerald
Flora Growth initiated with a Neutral at Cantor Fitzgerald
06/16/22 Roth Capital
Roth Capital views Flora Growth $5M share buyback 'favorably'
10/13/21 Roth Capital
Flora Growth initiated with a Buy at Roth Capital
CVSI CV Sciences
/

+

DLTNF Delta 9 Cannabis
/

+

IMCC IM Cannabis
/

+

08/16/22 Alliance Global Partners
IM Cannabis price target lowered to $1.50 from $6 at Alliance Global Partners
11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
MEDIF Medipharm Labs
/

+

05/17/22 Canaccord
Medipharm Labs price target lowered to C$0.10 from C$0.20 at Canaccord
04/04/22 Canaccord
Medipharm Labs price target lowered to C$0.20 from C$0.35 at Canaccord
04/01/22 Alliance Global Partners
Medipharm Labs price target lowered to C$0.25 from C$0.35 at Alliance Global Partners
11/16/21 Canaccord
Medipharm Labs downgraded to Hold from Speculative Buy at Canaccord
FFNTF 4Front Ventures
/

+

INCR InterCure
$5.78 /

-0.04 (-0.69%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
NEPT Neptune Wellness
$3.07 /

+1.71 (+125.74%)

07/01/22 Alliance Global Partners
Neptune Wellness downgraded to Neutral from Buy at Alliance Global Partners
11/17/21 Desjardins
Neptune Wellness price target lowered to C$0.75 from C$1.00 at Desjardins
PLNHF Planet 13 Holdings
$1.69 /

-0.1 (-5.59%)

GNLN Greenlane
$3.45 /

-0.13 (-3.63%)

08/17/22 Alliance Global Partners
Greenlane price target raised to $6 from $1.50 at Alliance Global Partners
08/17/22 Canaccord
Greenlane price target lowered to $5 from $20 at Canaccord
04/01/22 Canaccord
Greenlane price target lowered to $1 from $2 at Canaccord
04/01/22 Cowen
Greenlane price target lowered to $2 from $5 at Cowen
NDVAF INDIVA
/

+

04/21/22 Raymond James
INDIVA price target lowered to C$0.60 from C$1.25 at Raymond James
10/15/21 Raymond James
INDIVA downgraded to Outperform from Strong Buy at Raymond James
VRNOF Verano Holdings
$5.61 /

-0.09 (-1.58%)

08/16/22 Alliance Global Partners
Verano Holdings price target lowered to C$16 from C$27 at Alliance Global Partners
07/29/22 Needham
Verano Holdings cut to Hold at Needham on unresolved financial reporting issues
07/29/22 Needham
Verano Holdings downgraded to Hold from Buy at Needham
07/22/22 Seaport Global
Verano Holdings initiated with a Buy at Seaport Global
CRLBF Cresco Labs
$3.63 /

-0.12 (-3.20%)

08/18/22 Canaccord
Cresco Labs price target lowered to C$8 from C$9.50 at Canaccord
08/18/22 Piper Sandler
Cresco Labs price target lowered to $6 from $9 at Piper Sandler
08/17/22 Alliance Global Partners
Cresco Labs price target lowered to C$10 from C$15 at Alliance Global Partners
05/19/22 Canaccord
Cresco Labs price target lowered to C$9.50 from C$12 at Canaccord
AYRWF Ayr Wellness
$4.54 /

-0.09325 (-2.01%)

07/22/22 Seaport Global
Ayr Wellness initiated with a Buy at Seaport Global
03/18/22 Canaccord
Ayr Wellness price target lowered to C$40 from C$57 at Canaccord
03/03/22 Needham
Ayr Wellness price target lowered to $28 from $35 at Needham
12/20/21 Needham
Ayr Wellness named Cannabis Top Pick for 2022 at Needham
ATAI Atai Life Sciences
$4.61 /

+0.09 (+1.99%)

05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
RVLWF Revitalist Lifestyle and Wellness
/

+

05/03/22 Clarus
Revitalist Lifestyle and Wellness price target lowered to C$0.20 at Clarus
10/25/21 Clarus
Revitalist Lifestyle and Wellness initiated with a Speculative Buy at Clarus
AWKNF Awakn Life Sciences
/

+

04/01/22 Stifel
Awakn Life Sciences initiated with a Speculative Buy at Stifel
02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
TLRY Tilray
$3.95 /

-0.105 (-2.59%)

07/29/22 Cowen
Tilray price target lowered to $9 from $23 at Cowen
07/29/22 Benchmark
Tilray cut to Sell at Benchmark on continued deterioration in core business
07/29/22 Benchmark
Tilray downgraded to Sell from Hold at Benchmark
07/15/22 Roth Capital
Tilray price target lowered to $4 from $8 at Roth Capital
ACB Aurora Cannabis
$1.66 /

-0.08 (-4.60%)

06/24/22 Cantor Fitzgerald
Cantor upgrades Aurora to Overweight on potential catalyst in Germany
06/24/22 Cantor Fitzgerald
Aurora Cannabis upgraded to Overweight from Neutral at Cantor Fitzgerald
06/06/22 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
CTST CannTrust
/

+

CGC Canopy Growth
$3.80 /

-0.27 (-6.64%)

08/08/22 Canaccord
Canopy Growth price target lowered to C$2.75 from C$3.50 at Canaccord
08/08/22 Piper Sandler
Canopy Growth price target lowered to $2.50 from $3 at Piper Sandler
07/01/22 Canaccord
Canopy Growth price target lowered to C$3.50 from C$4.50 at Canaccord
07/01/22 Canaccord
Canopy Growth price target lowered to C$3.50 from C$4.50 at Canaccord
CRON Cronos Group
$3.10 /

-0.105 (-3.28%)

07/28/22 Canaccord
Cronos Group upgraded to Buy from Hold at Canaccord
05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
IGC India Globalization Capital
/

+

TCNNF Trulieve Cannabis
$12.81 /

-0.38 (-2.88%)

08/11/22 Canaccord
Trulieve Cannabis price target lowered to C$57 from C$65 at Canaccord
08/11/22 Stifel
Trulieve Cannabis price target lowered to C$36.50 from C$40 at Stifel
08/11/22 Craig-Hallum
Trulieve Cannabis price target lowered to $32 from $40 at Craig-Hallum
08/11/22 Cowen
Trulieve Cannabis price target lowered to $24 from $65 at Cowen
ZYNE Zynerba
$1.24 /

-0.075 (-5.70%)

06/23/22 Canaccord
Zynerba price target raised to $11 from $9 at Canaccord
CMPS Compass Pathways
$16.95 /

-0.02 (-0.12%)

08/05/22 Cantor Fitzgerald
Compass Pathways price target lowered to $35 from $58 at Cantor Fitzgerald
08/05/22 Citi
Compass Pathways price target lowered to $46 from $49 at Citi
02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
RLMD Relmada Therapeutics
$27.56 /

-0.52 (-1.85%)

05/09/22 Oppenheimer
Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
12/20/21 SVB Securities
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
GDNSF Goodness Growth
$1.11 /

-0.033 (-2.89%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
ZYNE Zynerba
$1.24 /

-0.075 (-5.70%)

VRNOF Verano Holdings
$5.61 /

-0.09 (-1.58%)

TLRY Tilray
$3.95 /

-0.105 (-2.59%)

TCNNF Trulieve Cannabis
$12.81 /

-0.38 (-2.88%)

RLMD Relmada Therapeutics
$27.56 /

-0.52 (-1.85%)

PLNHF Planet 13 Holdings
$1.69 /

-0.1 (-5.59%)

INCR InterCure
$5.78 /

-0.04 (-0.69%)

IMCC IM Cannabis
/

+

GTBIF Green Thumb Industries
$10.47 /

-0.6 (-5.42%)

GNLN Greenlane
$3.45 /

-0.13 (-3.63%)

FLGC Flora Growth
/

+

DLTNF Delta 9 Cannabis
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$3.10 /

-0.105 (-3.28%)

CMPS Compass Pathways
$16.95 /

-0.02 (-0.12%)

CGC Canopy Growth
$3.80 /

-0.27 (-6.64%)

AYRWF Ayr Wellness
$4.54 /

-0.09325 (-2.01%)

ATAI Atai Life Sciences
$4.61 /

+0.09 (+1.99%)

ACB Aurora Cannabis
$1.66 /

-0.08 (-4.60%)

  • 27
    May
  • 09
    Dec
  • 19
    Nov
CANN General Cannabis
/

+

TLRY Tilray
$3.95 /

-0.105 (-2.59%)

TCNNF Trulieve Cannabis
$12.81 /

-0.38 (-2.88%)

INCR InterCure
$5.78 /

-0.04 (-0.69%)

FLGC Flora Growth
/

+

FFNTF 4Front Ventures
/

+

DLTNF Delta 9 Cannabis
/

+

CRON Cronos Group
$3.10 /

-0.105 (-3.28%)

CRLBF Cresco Labs
$3.63 /

-0.12 (-3.20%)

CCHWF Columbia Care
$1.82 /

-0.06 (-3.19%)

CANN General Cannabis
/

+

AYRWF Ayr Wellness
$4.54 /

-0.09325 (-2.01%)

AWKNF Awakn Life Sciences
/

+

TLRY Tilray
$3.95 /

-0.105 (-2.59%)

CRON Cronos Group
$3.10 /

-0.105 (-3.28%)

CGC Canopy Growth
$3.80 /

-0.27 (-6.64%)

ACB Aurora Cannabis
$1.66 /

-0.08 (-4.60%)

Recommendations
IM Cannabis price target lowered to $1.50 from $6 at Alliance Global Partners » 09:15
08/16/22
08/16
09:15
08/16/22
09:15
IMCC

IM Cannabis

/

+

Alliance Global Partners…

Alliance Global Partners analyst Aaron Grey lowered the firm's price target on IM Cannabis to $1.50 from $6 and keeps a Buy rating on the shares. He is applying a lower multiple to his estimates given risk for the company to reach its near-term profitability targets as well as a potential slowdown of industry sales amid oversupply and pricing pressure in the Israeli market, Grey tells investors. He also notes that the company's current $6M cash position at the quarter end and continued losses could put the company in a position to need to raise capital.

ShowHide Related Items >><<
IMCC IM Cannabis
/

+

IMCC IM Cannabis
/

+

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
/

+

Hot Stocks
IM Cannabis receives Nasdaq notice of non-compliance » 08:05
07/19/22
07/19
08:05
07/19/22
08:05
IMCC

IM Cannabis

/

+

IM Cannabis announced…

IM Cannabis announced that the company received written notification from The Nasdaq Stock Market on July 13 that the company is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the company's common shares for the 30 consecutive business days from May 27 to July 12, the company no longer meets the minimum bid price requirement.

ShowHide Related Items >><<
IMCC IM Cannabis
/

+

IMCC IM Cannabis
/

+

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
/

+

Over a quarter ago
Conference/Events
IM Cannabis management to meet virtually with Roth Capital » 04:55
04/26/22
04/26
04:55
04/26/22
04:55
IMCC

IM Cannabis

$1.30 /

-0.06 (-4.41%)

Virtual Meeting to be…

Virtual Meeting to be held on April 26 hosted by Roth Capital.

ShowHide Related Items >><<
IMCC IM Cannabis
$1.30 /

-0.06 (-4.41%)

IMCC IM Cannabis
$1.30 /

-0.06 (-4.41%)

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
$1.30 /

-0.06 (-4.41%)

IMCC IM Cannabis
$1.30 /

-0.06 (-4.41%)

Conference/Events
IM Cannabis management to meet virtually with Roth Capital » 14:40
04/22/22
04/22
14:40
04/22/22
14:40
IMCC

IM Cannabis

$1.48 /

-0.11 (-6.92%)

Virtual Meeting to be…

Virtual Meeting to be held on April 26 hosted by Roth Capital.

ShowHide Related Items >><<
IMCC IM Cannabis
$1.48 /

-0.11 (-6.92%)

IMCC IM Cannabis
$1.48 /

-0.11 (-6.92%)

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
$1.48 /

-0.11 (-6.92%)

IMCC IM Cannabis
$1.48 /

-0.11 (-6.92%)

Hot Stocks
IM Cannabis' CEO and founder acquires 150.000 common shares of the company » 08:34
04/12/22
04/12
08:34
04/12/22
08:34
IMCC

IM Cannabis

$2.10 /

-0.06 (-2.78%)

Oren Shuster, CEO,…

Oren Shuster, CEO, director and founder of IM Cannabis announces that he has acquired an aggregate of 150,000 common shares in the capital of IMCC in a series of open market transactions between April 5 and 8 through the facilities of the Nasdaq Capital Market. Shuster acquired the Common Shares at an average price of $2.238 per Common Share for an aggregate purchase price of $335,731.60. Immediately prior to the Acquisition, Shuster held beneficial ownership of, or control or direction over, 9,135,137 Common Shares, representing 13.11% of the issued and outstanding Common Shares on a non-diluted basis and 14.71% of the Common Shares on a partially diluted basis. As a result of the Acquisition, Shuster now holds beneficial ownership of, or control or direction over, an aggregate of 9,285,137 Common Shares, representing approximately 13.32% of the issued and outstanding Common Shares on a non-diluted basis and 14.93% of the Common Shares on a partially diluted basis.

ShowHide Related Items >><<
IMCC IM Cannabis
$2.10 /

-0.06 (-2.78%)

IMCC IM Cannabis
$2.10 /

-0.06 (-2.78%)

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
$2.10 /

-0.06 (-2.78%)

IMCC IM Cannabis
$2.10 /

-0.06 (-2.78%)

Earnings
IM Cannabis sees Q1 revenue to increase sequentially  08:05
03/31/22
03/31
08:05
03/31/22
08:05
IMCC

IM Cannabis

$2.37 /

+0.19 (+8.72%)

 
ShowHide Related Items >><<
IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

Earnings
IM Cannabis reports Q4 EPS C$0.19 vs. C$0.13 a year ago » 08:04
03/31/22
03/31
08:04
03/31/22
08:04
IMCC

IM Cannabis

$2.37 /

+0.19 (+8.72%)

Reports Q4 revenue…

Reports Q4 revenue C$20.0M vs. $4.9M a year ago. "Our revenue growth of 242% to a record of over $54M in 2021 is a direct result of executing on our strategy to build a world-class operating platform for the premium cannabis market," said CEO Oren Shuster. "The network of pharmacies we have acquired in Israel, which includes the country's largest online pharmacy business, supports a tech-enabled expansion of our patient base to fortify our position as one of the leading retail medical cannabis providers in the country. In Canada, our premium WAGNERS brand and ultra-premium Highland Grow continue to gain market share, with retail sales in Ontario increasing over 50% in Q4 2021 as compared to Q3 2021. Looking forward, we expect revenues in the first quarter to accelerate sequentially and year-over-year, setting the stage for a robust year for IMC. As we see the increasing benefits from our integrated global platform materialize, we expect to achieve positive cash flow and adjusted EBITDA in the second quarter. We are focused on unifying our brands under the same high standards that we have always prioritized, which we believe will contribute to IMC's leadership position in the premium cannabis industry while ultimately driving sustainable value for our shareholders."

ShowHide Related Items >><<
IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

IMCC IM Cannabis
$2.37 /

+0.19 (+8.72%)

Earnings
IM Cannabis sees FY21 revenue at least $54M, one estimate $40.74M  08:04
03/10/22
03/10
08:04
03/10/22
08:04
IMCC

IM Cannabis

$1.91 /

-0.13 (-6.37%)

 
ShowHide Related Items >><<
IMCC IM Cannabis
$1.91 /

-0.13 (-6.37%)

IMCC IM Cannabis
$1.91 /

-0.13 (-6.37%)

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
$1.91 /

-0.13 (-6.37%)

IMCC IM Cannabis
$1.91 /

-0.13 (-6.37%)

Earnings
IM Cannabis sees Q4 revenue at least $20M, one estimate $14.16M » 08:03
03/10/22
03/10
08:03
03/10/22
08:03
IMCC

IM Cannabis

$1.91 /

-0.13 (-6.37%)

"We built…

"We built significant momentum across our operating platform in 2021, as evidenced by our annual revenues growth of at least 240% to a record of at least $54M," said CEO Oren Shuster. "In Israel, we have become among the largest distributors of medical cannabis and are well positioned to capture market growth today and in the future with the potential for recreational legalization. We continue to capture meaningful market share in the premium segment in Canada driven by our staunch focus on cultivation excellence and increasing brand recognition of WAGNERS and Highland Grow. Importantly, our execution with our recreational and medical operations in Canada and Israel and our global distribution expertise provides us with the blueprint to effectively capitalize on the substantial German market opportunity as it liberalizes its cannabis laws. As we move through 2022, we remain focused on realizing synergies across our supply chain while scaling operations in the three largest federally legal markets where we currently operate, which makes IMC uniquely positioned to emerge as the leading purveyor of premium cannabis on a global scale. I look forward to providing further updates to the market during our upcoming earnings call later this month".

ShowHide Related Items >><<
IMCC IM Cannabis
$1.91 /

-0.13 (-6.37%)

IMCC IM Cannabis
$1.91 /

-0.13 (-6.37%)

11/17/21 Desjardins
IM Cannabis price target lowered to C$9.25 from C$10.25 at Desjardins
10/05/21 Roth Capital
IM Cannabis initiated with a Buy at Roth Capital
08/18/21 Desjardins
IM Cannabis price target lowered to C$10.25 from C$10.50 at Desjardins
08/17/21 Alliance Global Partners
IM Cannabis price target lowered to $8 from $10 at Alliance Global Partners
IMCC IM Cannabis
$1.91 /

-0.13 (-6.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.